Clinical study of Siddha drug MADHUMEGA KUDINEER (Internal) in the treatment of SINAIPAINEERKATTI

Clinical evaluation of Siddha drug MADHUMEGA KUDINEER (Internal) in the treatment of SINAIPAINEERKATTI (Polycystic Ovarian Syndrome)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/07/008965

Enrollment

Registered

2017-07-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with the symptoms of Irregular menstrual cycle, hirsutism, obesity, polycystic changes in ovaries

Interventions

Intervention1: Madhumega kudineer: Madhumega kudineer is the polyherbal drug. Ingredients are 1.KEELKAAI NELLI(Phyllanthus amarus) 2.NELLI (Emblica officinalis) 3.KARIVEMBBU (Murraya koenigii) 4.KADUK

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients who are having the clinical symptoms of Oligomenorrhoea (or) Amenorrhoea (or) obesity or infertility with polycystic changes in ovaries. 2.USG pelvis showing polycystic ovaries. 3.Patient willing to participate in trial and signing in consent form

Exclusion criteria

Exclusion criteria: 1.H/O hypertension 2.Ovarian cancer 3.Pregnancy and lactation 4.H/O thyroid dysfunction 5.Patient with any serious illness 6.Fibroid uterus

Design outcomes

Primary

Measure	Time frame
1.Regular menstrual cycle. 2.Reduction in BMI Timepoint: 90 Days	—

Secondary

Measure	Time frame
Changes in the polycystic appearance of the ovaries in USG pelvis and reduction of other symptoms such as Obesity, infertility, etc.Timepoint: 90 Days	—

Countries

India

Contacts

Public ContactDr A M Amala Hazel

National Institute of siddha

mmssiddha@gmail.com9444214582

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026